Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon beta in multiple sclerosis

B G Arnason1

  • 1Pritzker School of Medicine and the Brain Research Institute, University of Chicago, Illinois 60637, USA.

Clinical Immunology and Immunopathology
|October 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Neurology·2003
Same author

Design and expression of polymeric immunoglobulin fusion proteins: a strategy for targeting low-affinity Fcgamma receptors.

Protein expression and purification·2001
Same author

Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis.

Archives of neurology·2001
Same author

Interactions between the sympathetic nervous system and the immune system.

Brain, behavior, and immunity·1999
Same author

Treatment of multiple sclerosis with interferon beta.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·1999
Same author

Immunologic therapy of multiple sclerosis.

Annual review of medicine·1999
Same journal

Mechanisms of virus replication, persistence, and regulation of immune responses.

Clinical immunology and immunopathology·2020
Same journal

Cumulative subject index for volumes 86-89

Clinical immunology and immunopathology·1998
Same journal

D-penicillamine-induced pancreatic islet autoantibody production is independent of the immunogenetic background: a lesson from patients with Wilson's disease.

Clinical immunology and immunopathology·1998
Same journal

Characterization of gastric Na+/I- symporter of the rat.

Clinical immunology and immunopathology·1998
Same journal

CD8(+), radiosensitive T cells of parental origin, oppose cells capable of down-regulating cytotoxicity in murine acute lethal graft-versus-host disease.

Clinical immunology and immunopathology·1998
Same journal

Specific activity of alpha1proteinase inhibitor and alpha2macroglobulin in human serum: application to insulin-dependent diabetes mellitus.

Clinical immunology and immunopathology·1998
See all related articles

Interferon beta 1B (IFNbeta1b) modulates the immune system to reduce multiple sclerosis (MS) relapses and disease progression. It works by dampening T-cell responses and enhancing suppressor cell function, offering a beneficial effect in MS patients.

Area of Science:

  • Immunology
  • Neuroimmunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is an immune-mediated disease characterized by T-cell involvement and delayed-type hypersensitivity (DTH) responses.
  • The immune response in MS is thought to be driven by Th1-type T cells and activated macrophages.
  • Current understanding suggests a need for immunomodulatory therapies targeting specific immune pathways in MS.

Purpose of the Study:

  • To elucidate the immunomodulatory mechanisms of Interferon beta 1B (IFNbeta1b) in the context of multiple sclerosis (MS).
  • To investigate how IFNbeta1b affects antigen presentation, T-cell activation, and cytokine profiles relevant to MS pathogenesis.
  • To correlate the observed immunomodulatory effects with the clinical benefits of IFNbeta1b in MS.

Main Methods:

Related Experiment Videos

  • Analysis of IFNbeta1b's effects on MHC-class II expression on monocytes.
  • Assessment of IFNbeta1b's impact on B7-1 costimulatory molecule expression on B cells.
  • Evaluation of IFNbeta1b's influence on T-cell proliferation and cytokine production (IL-2, IFNgamma, LT, TNF, IL-10, TGF-beta1) in vitro.
  • Examination of IFNbeta1b's effects on CD8 cell function, including suppressor cells.

Main Results:

  • IFNbeta1b reduces MHC-class II expression on monocytes, potentially impairing antigen presentation.
  • IFNbeta1b downregulates B7-1 expression on B cells, which may inhibit Th1 cell activation.
  • IFNbeta1b exhibits antiproliferative effects on T cells and alters cytokine profiles, decreasing IFNgamma, LT, and TNF while increasing IL-2, IL-10, and TGF-beta1.
  • IFNbeta1b enhances CD8 cell function, including that of suppressor cells.

Conclusions:

  • The combined immunomodulatory actions of IFNbeta1b are expected to attenuate DTH responses, a key component of MS pathogenesis.
  • IFNbeta1b's effects on antigen presentation, T-cell activation, and cytokine balance contribute to its beneficial clinical outcomes in MS.
  • IFNbeta1b represents a valuable therapeutic agent for MS by modulating critical immune pathways involved in the disease.